Post-hoc analysis of data from 3,330 patients who received 5 mg or 10 mg tofacitinib twice daily for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in phase II and III studies reveals that tofacitinib treatment was associated with rapid and sustained alleviation of pain. Overall, improvements were seen in all pain assessments (including unidimensional pain measures and individual pain components of multidimensional measures) with tofacitinib treatment compared with placebo. Tofacitinib reduced pain at both dosages and regardless of inadequate response to previous treatments.
References
Original article
Ogdie, A. et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open 6, e001042 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Tofacitinib alleviates pain in RA, PsA and AS. Nat Rev Rheumatol 16, 186 (2020). https://doi.org/10.1038/s41584-020-0392-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0392-6
This article is cited by
-
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Arthritis Research & Therapy (2021)